Treatment of Parkinson’s: Guillaume Brechet from Tours founded his start-up and raised 400,000 euros

The year 2024 is off to a good start, even for Guillaume Brechet, our Fondates researcher, who suffers from Parkinson’s and has discovered a treatment to slow down the progression of the disease.

Since we have been talking to you about it regularly he has made his fight known, first with him A year ago his trip to the Loire by kayak was a bit more To communicate about your project. We told you that a few months ago The results of his first tests were very encouraging. Here it is Guillaume Brachet has now created his own start-up

To advance these potential treatments to clinical trials.

“We raised our first fund in just three months”

“A start-up known today as CXS Therapeutics, located in Touraine in Fondettes, was created in September with the possibility of developing a treatment against Parkinson’s disease. And so, from September, on the one hand we created the structure, administratively speaking. , the other four with the co-founders. We raised our first fund in just three months, which allowed us to raise 400,000 euros which allowed us to start working. And then we submitted a European patent application specifically for this treatment against which we developed doing. The tremors.”

Guillaume Brachet explains.

European Patent Application

A response to this definitive patent application, with twenty years of protection for their idea, is expected in late February/early March. But with his start-up, Guillaume Brechet does not intend to stop at Parkinson’s disease. “This working method that sets out to use information from the scientific literature to find drugs in pharmacy trays that already exist and that may be of interest in the treatment of incurable neurological diseases, we’re going to duplicate that, we’re going to transfer that. Other pathologies, always in the neurological field. We will apply it to other diseases, hoping to find solutions to existing drugs for pathologies for which we still know nothing to do.”. Like for example multiple sclerosis.

If Guillaume Brechet’s obstacle course ends, and his treatment is commercialized, it So it could be the first in the world to slow the progression of Parkinson’s diseaseThe first in the world to be able to attack evil at the root, and not just mask the symptoms.